Navigation Links
China-Biotics Appoints New Chief Operating Officer

SHANGHAI, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" or "the Company"), (Nasdaq: CHBT) the leading developer, manufacturer and distributor of probiotics products in China, today announced the appointment of Dr. Hui S. Chang as Chief Operating Officer, effective immediately.

Dr. Chang brings 15 years of biopharmaceutical project management experience and excellent research capabilities. Prior to joining China-Biotics, Dr. Chang served as the president of a consulting service for a Sino-U.S. joint biopharmaceutical program, where he led the scientific design, development, clinical trials, production and quality control for viral vaccines and antibodies. He reported to the State Administration of Foreign Experts Affairs and played a key role in generating profits on the completed contract. Dr. Chang was previously a senior manager of Nabi Biopharmaceuticals, where he supervised the development and production of bacterial and viral vaccines, developed biological potency and immunological methods and managed the development of assays for quality control and clinical testing. Earlier, Dr. Chang served as a manager at Vaccinnate, a North American bio-vaccine company, where he led the design, GMP production and clinical testing of viral vaccines. Previously, Dr. Chang was a research scientist with Cambridge Biotech, where he specialized in the production and quality control of monoclonal biological products, protein products as well as HIV and HTLV antigen. Dr. Chang started his professional career at North AM VAC Inc. in 1989.

Dr. Chang holds a Ph.D. in vaccine development focusing on biochemistry and immunology as well as an MBA with concentration in finance and logistics in the vaccine industry from Johns Hopkins University. He also has a Bachelor of Science in biology from the University of Maryland. Dr. Chang has also received certified training in Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and Good Safety Practice (GSP) procedures. Dr. Chang is fluent in English and mandarin Chinese.

Mr. Jinan Song, Chairman and CEO of China-Biotics, commented, "We are very pleased that China-Biotics has been able to attract such a qualified candidate for this crucial position. Dr. Chang's solid biotech background, advanced project management track record, and his excellent knowledge in business and finance will make him a strong COO and desirable addition to our team. China-Biotics continues to build a strong management team to support our expanding bulk business in both the dairy and animal feed markets in China."

About China-BioticsChina-Biotics, Inc. ("China-Biotics" or "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces its proprietary product portfolio. Currently, the retail products are sold OTC mainly through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The Company also sells bulk products to institutional customers such as dairy and animal feed producers, as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit .Contact:Travis Cai Chief Financial OfficerChina-Biotics, Inc.traviscai@chn-biotics.comShiwei Yin/Dixon Chen

SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics to Report Fiscal Year 2011 Second Quarter Financial Results on November 9
2. China-Biotics Hosted its First Investor Day Event
3. China-Biotics Ranked Number 62 on FORTUNES 100 Fastest-Growing Companies List
4. China-Biotics to Report Fiscal Year 2011 First Quarter Financial Results on August 9
5. China-Biotics Provides Further Updates on Qingpu New Facility
6. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
7. China-Biotics to Report Fourth Quarter and Fiscal Year 2010 Financial Results on June 11
8. China-Biotics to Present at Bank of America Merrill Lynch Healthcare Event on June 22
9. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
10. China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor
11. China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility
Post Your Comments:
(Date:10/9/2017)... , ... October 09, 2017 ... ... on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® ... gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... 2017 , ... The HealthTech Venture Network (HTVN) is proud ... annual Conference where founders, investors, innovative practitioners and collaborators are invited to a ... early stage digital health and med tech companies. , This day-long event will ...
(Date:10/5/2017)... YORBA LINDA, CA (PRWEB) , ... October 05, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is giving back to cancer ... shirt sold in October. , Now through October 31, shoppers can use promo ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):